TUSTIN, CA -- (MARKET WIRE) -- 02/09/12 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and infectious diseases, today announced that Steven King, its president and chief executive officer, is scheduled to present at the 14th Annual BIO CEO and Investor Conference in New York on Tuesday, February 14, 2012 at 8:30 AM Eastern Standard Time (EST).

Peregrine's presentation will be webcast live and available for replay until February 28, 2012 at: http://ir.peregrineinc.com/events.cfm

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer. The company is pursuing multiple clinical programs in cancer and infectious diseases with its lead product candidate bavituximab and novel brain cancer agent Cotara®. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.

Add to Digg Bookmark with del.icio.us Add to Newsvine

Contact:

Jay CarlsonPeregrine Pharmaceuticals

(800) 987-8256

info@peregrineinc.com

Source: Peregrine Pharmaceuticals

News Provided by Acquire Media